

INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF THE SPECIAL PURPOSE IND AS FINANCIAL STATEMENTS

To the Board of Directors of the Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)

Opinion

We have audited the accompanying special purpose Ind AS financial statements of **Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)** which comprise the Balance Sheet as at Sep. 30, 2025, and the Statement of Profit and Loss, statement of changes in equity and statement of cash flows for the period 1st April 2025 to 30th Sep. 2025 then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the special purpose Ind AS financial statements for the Period 1st April 2025 to 30th Sep. 2025 are prepared, in all material respects, in accordance with the basis of preparation described in Note 1.2 to those special purpose Ind AS financial statements.

Basis for Opinion

We conducted our audit of the special purpose Ind AS financial statements in accordance with the Standards on Auditing (SAs), as issued by the Institute of Chartered Accountants of India ("ICAI"). Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the special purpose Ind AS financial statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the special purpose Ind AS financial statements.

Emphasis of matter

We draw attention to Note 1.2 to the financial statements, which describes the basis of preparation of these special purpose Ind AS financial statements which states that these special purpose Ind AS financial statements have been prepared by the Company for submission to the National Company Law Tribunal for proposed Scheme of Arrangement involving India Glycols Limited, Ennature Bio Pharma Limited and IGL Spirits Limited as at 30th Sep. 2025 and for the period ended 1st April 2025 to 30th Sep. 2025. Accordingly, the attached financial statements may not be suitable for any other purpose and this report should not be used, referred to or distributed for any other purpose. We have no responsibility to update this report for events and circumstances occurring after the date of this report.

Our opinion is not modified in respect of these matter.



KOLKATA OFF. : 6-C, Middleton Street, Flat No. 23, IInd Floor, KOLKATA-700071

K.N. GUTGUTIA & CO.

CHARTERED ACCOUNTANTS

NEW DELHI : KOLKATA

**11-K, GOPALA TOWER, 25, RAJENDRA PLACE,
NEW DELHI-110008**

Phones : 25713944, 25788644, 25818644

E-mail : brg1971@cakng.com, kng1971@yahoo.com

Website : www.cakng.com

Responsibilities of Management for the special purpose Ind AS Financial Statements

The Company's Board of Directors is responsible for the preparation of these special purpose Ind AS financial statements prepared in accordance with the basis of preparation as stated in Note 1.2 This responsibility also includes maintenance of adequate accounting records for safeguarding of the assets of the Company for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the special purpose Ind AS financial statements and are free from material misstatement, whether due to fraud or error.

In preparing the special purpose Ind AS financial statements, the Board of Directors of the company responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors of the company are also responsible for overseeing the financial reporting process.

Auditor's Responsibilities for the Audit of the special purpose Ind AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the special purpose Ind AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these special purpose Ind AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the special purpose Ind AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.



KOLKATA OFF. : 6-C, Middleton Street, Flat No. 23, 11nd Floor, KOLKATA-700071

K.N. GUTGUTIA & CO.

CHARTERED ACCOUNTANTS

NEW DELHI : KOLKATA

**11-K, GOPALA TOWER, 25, RAJENDRA PLACE,
NEW DELHI-110008**

Phones : 25713944, 25788644, 25818644

E-mail : brg1971@cakng.com, kng1971@yahoo.com

Website : www.cakng.com

If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the special purpose Ind AS financial statements, including the disclosures, and whether the special purpose Ind AS financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For K. N. Gutgutia & Co.

Chartered Accountants

ICAI Firm Registration Number: 304153E


B. R. Goyal

Partner

Membership Number: 012172

UDIN: 2601217220EBJP1916



Place of Signature: New Delhi

Date: 21/01/2026

Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Balance Sheet as at Sep 30, 2025

(₹ in Lakhs)

Particulars	Note No.	As at Sep 30, 2025	As at March 31, 2025
ASSETS			
CURRENT ASSETS:			
(a) Financial Assets			
(i) Cash and cash equivalents	2	-	-
TOTAL ASSETS		-	-
EQUITY AND LIABILITIES			
EQUITY:			
(a) Equity Share capital	3	1.00	1.00
(b) Other Equity	3A	(1.43)	(1.36)
		(0.43)	(0.36)
LIABILITIES:			
CURRENT LIABILITIES:			
(a) Financial Liabilities			
(i) Other financial liabilities	4	0.43	0.36
		0.43	0.36
TOTAL EQUITY AND LIABILITIES		-	-

Company Overview & Summary of material accounting policies 1

The accompanying notes are an integral part of these financial statements.


As per our report of even date

For K N GUTGUTIA & CO.
 CHARTERED ACCOUNTANTS
 FRN: 304153E


B R GOYAL
 PARTNER
 M. NO. 012172

Place - Noida (UP)
 Date - 21/01/2026

For and on behalf of the board
 of Ennature Bio Pharma Limited


Manish Chandra Pant
 Director
 DIN - 08850173


Shashi Kant Shukla
 Director
 DIN - 07117368



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Statement of Profit & Loss for the half year ended Sep 30, 2025

(₹ in Lakhs)

Particulars	Note No.	Half year ended Sep 30, 2025	Year ended March 31, 2025
Revenue from operations		-	-
Other income		-	-
Total Income		-	-
Expenses:			
Other expenses	5	0.07	0.17
Total Expenses		0.07	0.17
Profit/ (Loss) before tax		(0.07)	(0.17)
Tax Expense:			
- Current Tax		-	-
- Deferred Tax		-	-
Profit/ (Loss) for the period		(0.07)	(0.17)
Other Comprehensive Income			
A (i) Items that will not be reclassified to Profit or Loss		-	-
(ii) Income tax relating to items that will not be reclassified to Profit or Loss		-	-
B (i) Items that will be reclassified to Profit or Loss		-	-
(ii) Income tax relating to items that will be reclassified to Profit or Loss		-	-
Other comprehensive Income/ (Loss) for the period		-	-
Total Comprehensive Income for the period		(0.07)	(0.17)
Earnings per Equity share (face value of Rs. 5 each) Basic/ diluted (in Rs.)	10	(0.35)	(0.85)

Company Overview & Summary of material accounting policies 1

The accompanying notes are an integral part of these financial statements.

As per our report of even date


For K N GUTGUTIA & CO.
 CHARTERED ACCOUNTANTS
 FRN: 304153E



 B R GOYAL
 PARTNER
 M. NO. 012172

Place - Noida (UP)
 Date - 21/01/2026



For and on behalf of the board
 of Ennature Bio Pharma Limited


 Manish Chandra Pant
 Director
 DIN - 08850173


 Shashi Kant Shukla
 Director
 DIN - 07117368

Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Cash Flow Statement for the half year ended Sep 30, 2025

(₹ in Lakhs)

Particulars	Hal year ended Sep 30, 2025	Year ended March 31, 2025
A Cash Flow from Operating Activities		
Net Profit/ (Loss) Before Tax	(0.07)	(0.17)
Operating Profit/ (Loss) before Working Capital Changes	(0.07)	(0.17)
Adjustments For:		
Increase / (Decrease) in Trade & Other Payables	0.07	0.17
Cash Generated from / (Used in) Operations	-	-
Income Tax Paid (Net)	-	-
Net Cash flow generated from / (Used in) Operating Activities	-	-
B Cash Flow from Investing Activities		
Net Cash flow generated from / (Used in) Investing Activities	-	-
C Cash Flow from Financing Activities		
Proceeds from Issue of Share Capital	-	-
Net Cash flow generated from / (Used in) Financing Activities	-	-
Net Increase/(Decrease) in Cash & Cash Equivalents [A+B+C]	-	-
Opening Cash & Cash Equivalents (refer note 2)	-	-
Closing Cash & Cash Equivalents (refer note 2)	-	-


Note:-


- The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of Cash Flows.

As per our report of even date
For K N GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
FRN: 304153E


B R GOYAL
PARTNER
M. NO. 012172

For and on behalf of the board
of Ennature Bio Pharma Limited


Manish Chandra Pant
Director
DIN - 08850173


Shashi Kant Shukla
Director
DIN - 07117368

Place - Noida (UP)
Date - 21/01/2026



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Statement of Changes in Equity for the half year ended Sep 30, 2025

A. Equity Share Capital

(₹ in Lakhs)

Particulars	Balance as at April 01, 2025	Changes in equity share capital during the period	Balance as at 30th Sep 2025
20,000 Equity Shares of Rs. 5/- each fully paid up	1.00	-	1.00
	1.00	-	1.00

Particulars	Balance as at April 01, 2024	Changes in equity share capital during the year	Balance as at 31st March 2025
10,000 Equity Shares of Rs. 10/- each fully paid up	1.00	-	1.00
	1.00	-	1.00

B. Other Equity

(₹ in Lakhs)

Particulars	Reserves and Surplus	
	Retained Earnings	Total
Balance As at March 31, 2024	(1.19)	(1.19)
Profit / (Loss) for the year	(0.17)	(0.17)
Other Comprehensive Income for the year	-	-
Balance As at March 31, 2025	(1.36)	(1.36)
Profit / (Loss) for the period	(0.07)	(0.07)
Other Comprehensive Income for the period	-	-
Balance As at Sep 30, 2025	(1.43)	(1.43)

As per our report of even date

For K N GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
FRN: 304153E

B.R.Goyal
Partner
M.No. 012172

Place - Noida (UP)
Date - 21/01/2026



For and on behalf of the board
of Ennature Bio Pharma Limited

Mandeep Chandra Pant
Director
DIN - 08850173

Shashi Kant Shukla
Director
DIN - 07117368

Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to the financial statements for the half year ended September 30, 2025

1.1 Corporate Information

Ennature Bio Pharma Limited is a limited company domiciled in India, incorporated under the provisions of Companies Act, 2013. It is subsidiary company of India Glycols Limited, a company incorporated in India.

1.2 STATEMENT OF MATERIAL ACCOUNTING POLICIES

A. Basis of Preparation and Presentation of Financial Statements

These financial statements have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended. The special purpose Ind AS financial statements have been prepared by the Company as at 30th September 2025 for submission to the National Company Law Tribunal for the purpose of proposed Scheme of Arrangement involving India Glycols Limited, Ennature Bio Pharma Limited and IGL Spirits Limited.

The Financial statements have been prepared and presented under the historical cost convention, on accrual and going concern basis, except for certain financial assets and liabilities that are measured at fair values at the end of each reporting period as required by relevant Ind- AS. The financial statements are presented in Indian Rupees, which is the Company's functional and presentation currency and all amounts are rounded to the nearest lakhs (00,000) and two decimals thereof, except as stated otherwise.


The accounting policies are applied consistently to all the periods presented in the financial statements. All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria as set out in the Division II of Schedule III to the Companies Act, 2013. The Company has ascertained its operating cycle as 12 months for the purpose of current or non-current classification of assets and liabilities.

Transactions and balances with values below the rounding off norm adopted by the Company have been reflected as "0" in the relevant notes in these financial statements.

The preparation of financial statements requires management to make judgments, estimates and assumptions in the application of accounting policies that affect the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision effects only that period or in the period of the revision and future periods if the revision affects both current and future years (refer Note no. 1.3 on significant accounting estimates, assumptions and judgments).

B. Financial instruments - initial recognition, subsequent measurement and impairment

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. A financial assets or a liability is recognised when the Company becomes a party to the contractual provision of the instrument.



a) Financial Assets

Financial assets include cash and cash equivalent, other receivables, investments in securities.

Financial Assets are measured at amortised cost or fair value through Other Comprehensive Income or fair value through Profit or Loss, depending on its business model for managing those financial assets and the assets contractual cash-flow characteristics.

Subsequent measurements of financial assets are dependent on initial categorisation. For impairment purposes significant financial assets are tested on an individual basis, other financial assets are assessed collectively in groups that share similar credit risk characteristics.

The company derecognizes a financial assets when the contractual rights to the cash flows from the financial assets expire or it transfers the financial assets and the transfer qualifies for the derecognition under Ind AS 109.

The company assesses impairment based on expected credit loss (ECL) model to all its financial assets measured at amortised cost.

b) Financial liabilities

Financial liabilities include short term loan and other payables.

All financial liabilities recognized initially at fair value and, in the case of loans and borrowing and other payable, net of directly attributable transaction costs. After initial recognition, financial liabilities are classified under one of the following two categories

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss. The Company has not designated any financial liabilities upon initial measurement recognition at fair value through profit or loss. Financial liabilities at fair value through profit or loss are at each reporting date at fair value with all the changes recognized in the Statement of Profit and Loss.

Financial liabilities measured at amortised cost

After initial recognition, such financial liabilities are subsequently measured at amortized cost by applying the Effective Interest Rate (EIR) method to the gross carrying amount of financial liability. The EIR amortization is included in finance expense in the statement of profit and loss.

De-recognition of financial liability

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires.



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to the financial statements for the half year ended September 30, 2025

C. Revenue recognition and other income

Revenue from contracts with Customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

D. Taxation

Income tax expense comprises current tax expense and the net change in the deferred tax asset or liability during the period. Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity, respectively.

(i) Current tax:

Current Tax expenses are accounted in the same period to which the revenue and expenses relate. Provision for current income tax is made for the tax liability payable on taxable income after considering tax allowances, deductions and exemptions determined in accordance with the applicable tax rates and the prevailing tax laws.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis.

(ii) Deferred tax :

Deferred income tax is recognised using the balance sheet approach. Deferred income tax assets and liabilities are recognised for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill, an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction.


Deferred income tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilised.

Minimum Alternative Tax ("MAT") credit is recognized as an asset only when and to the extent there is reasonable certainty that the Company will pay normal income tax during the specified period. Such asset is reviewed at each Balance Sheet date and the carrying amount of the MAT credit asset is written down to the extent there is no longer a reasonable certainty to the effect that the Company will pay normal income tax during the specified period.

E. Earnings Per Share:

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the period including potential equity shares on compulsory convertible debentures.

Diluted earnings per share is computed by adjusting the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) attributable to equity shareholders and the weighted average number of equity shares outstanding for the effects of all dilutive potential equity shares.



F. Accounting for Provisions, Contingent Liabilities and Contingent Assets:

Provisions are recognized, when there is a present legal or constructive obligation as a result of a past event, it is probable that an outflow of resources will be required to settle the obligation, and when a reliable estimate of the amount of the obligation can be made. If the effect of the time value of money is material, the provision is discounted using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation and the unwinding of the discount is recognised as interest expense.

Contingent liabilities are recognized only when there is a possible obligation arising from past events, due to occurrence or non-occurrence of one or more uncertain future events, not wholly within the control of the Company, or where any present obligation cannot be measured in terms of future outflow of resources, or where a reliable estimate of the obligation cannot be made. Obligations are assessed on an ongoing basis and only those having a largely probable outflow of resources are provided for.

Contingent assets are not recognized in the financial statements.

G. Cash and Cash Equivalent (for the purpose of cash flow statements)

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less), which are subject to insignificant risk of changes in value.

H. Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit/ (loss) before tax is adjusted for the effects of transactions of no cash nature and any deferrals or accruals of past or future cash receipts or payments. Cash flow for the period are classified by operating, investing and financing activities.

1.3 Critical accounting estimates, assumptions and judgments

The preparation of financial statements in conformity with Ind AS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses for the period presented. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to financial statements for the half year ended Sep 30, 2025

2. CASH & CASH EQUIVALENTS

(₹ in Lakhs)

Particulars	As at Sep 30, 2025	As at March 31, 2025
(i) Balance with Banks - On Current Accounts	-	-
	-	-



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to financial statements for the half year ended Sep 30, 2025

3. EQUITY SHARE CAPITAL

₹ in Lakhs except as otherwise stated

Particulars	As at Sep, 30	As at March, 31
	2025	2025
Authorised :		
100000 Equity Shares of Rs.5/- each (Previous Year 50000 Equity Shares of Rs.10/- each)	5.00	5.00
	5.00	5.00
Issued, Subscribed and paid up :		
20000 Equity Shares of Rs.5/- each fully paid-up * (Previous Year 10000 Equity Shares of Rs.10/- each fully paid-up)	1.00	1.00
*shares held by the holding Company, namely India Glycols Limited	1.00	1.00

a) Terms/rights attached to equity shares:

The Company has only one class of shares referred to as equity shares having par value of Rs.5/- per share (Previous year 10 per share). Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amount exists currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

b) Details of shareholders holding more than 5% equity shares in the company

Name of Shareholders	As at Sep 30, 2025		As at March 31, 2025	
	No. of Shares	% of holding	No. of Shares	% of holding
INDIA GLYCOLS LIMITED with Nominees	20000	100%	10000	100%
Total	20000	100%	10000	100%

c) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period

Particulars	No. of Shares As at Sep 30, 2025	No. of Shares As at March 31, 2025
Shares outstanding as at the beginning of the period	10,000	10,000
Shares Issued during the period	-	-
Shares bought back during the period	-	-
Add: Share Split in the ratio 1:2 (Face Value ₹10 to ₹5)	10,000	-
Shares outstanding as at the end of the period	20,000	10,000



d) Details of shares held by promoters of the company

Promoters Name	As at Sep 30, 2025		
	No. of shares	% of total shares	% change during the year
INDIA GLYCOLS LIMITED	20000	100%	0%

Promoters Name	As at March 31, 2025		
	No. of shares	% of total shares	% change during the year
INDIA GLYCOLS LIMITED	10000	100%	0%

e) Since incorporation there was no Bonus issue, buy back and /or issue of shares other than for cash consideration.

f) Share Split

The Board of Directors of the company at their meeting held on 30th May, 2025 had considered and approved the Stock Split of every one equity share having face value of Rs.10/- each, fully paid-up, into Two equity shares, having face value of Rs. 5/-each, fully paid-up and the same has been approved by the shareholders of the company on 23rd July 2025. Accordingly, the equity shares has been increased from 10,000 Equity shares to 20,000 Equity shares and as per Ind AS 33 Earning per Share, the Basic and Diluted EPS for the all previous periods have been restated considering the current number of equity shares with face value of Rs 5/- each.

3A. Other Equity

(₹ in Lakhs)

Particulars	Reserve & Surplus	
	Retained Earnings	Total
Balance As at March 31,2024	(1.19)	(1.19)
Profit / (Loss) for the year	(0.17)	(0.17)
Other Comprehensive Income for the year	-	-
Balance As at March 31, 2025	(1.36)	(1.36)
Profit / (Loss) for the period	(0.07)	(0.07)
Other Comprehensive Income for the period	-	-
Balance As at Sep 30, 2025	(1.43)	(1.43)

Nature & purpose of reserves

Retained Earnings - Retained earnings are the profits/(losses) that the Company has earned till date, less any transfers to general reserve, dividends or other distributions paid to shareholders.



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to financial statements for the half year ended Sep 30, 2025

4. OTHER FINANCIAL LIABILITIES

(₹ in Lakhs)

Particulars	As at Sep 30, 2025	As at March 31, 2025
Other Payables	0.43	0.36
	0.43	0.36



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to financial statements for the half year ended Sep 30, 2025

(₹ in Lakhs)

5. OTHER EXPENSES	Half year ended Sep 30, 2025	Year ended March 31, 2025
Audit Fees	0.06	0.12
Legal & Professional fees	-	0.03
Miscellaneous Expenses	0.01	0.02
	0.07	0.17



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to the financial statements for the half year ended September 30, 2025

6. Contingent Liabilities not provided For (As Certified by the Management): Nil (March 31, 2025: Nil).

7. Financial risk management objectives and Policies

• **Market Risk:**

Currently, the company has no business and hence the company is not exposed to market risk.

• **Credit Risk:**

Credit risk refers to risk that a counter party will default on its contractual obligations resulting in financial loss to the Company. Credit risk arises primarily from financial assets such as advance and other receivables. The Company does not have exposure to credit risk.

• **Liquidity Risk:**

Liquidity risk is the risk, where the company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The company is not exposed to liquidity risk.

• **Capital risk management**

The Company does not have capital risk.

8. Expenditure & Earning in Foreign Currency -NIL (March 31, 2025: Nil).

9. Fair valuation techniques

The Company maintains policies and procedures to value financial assets or financial liabilities using the best and most relevant data available. The fair values of the financial assets and liabilities are included at the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

(₹ in Lakhs)

Particular	As at 30.09.2025		As at 31.03.2025	
	Carrying amount	Fair Value	Carrying amount	Fair Value
(A) Financial Assets				
1. At fair value through profit & Loss	-	-	-	-
2. At Amortized Cost				
- Cash and cash equivalents	-	-	-	-
Total Financial Assets	-	-	-	-
(B) Financial Liabilities				
1. At fair value through profit & Loss	-	-	-	-
2. At Amortized Cost				
- Others	0.43	0.43	0.36	0.36
Total Financial Liabilities	0.43	0.43	0.36	0.36



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to the financial statements for the half year ended September 30, 2025

The methods and assumptions were used to estimate the fair values: Fair value of cash and bank balance, receivables, payables, and other financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

Fair Value hierarchy

All financial assets and liabilities for which fair value is measured in the financial statements are categorised within the fair value hierarchy, described as follows: -

Level 1 - Quoted prices in active markets.

Level 2 - Directly or indirectly observable market inputs, other than Level 1 inputs; and

Level 3 - Inputs which are not based on observable market data.

Assets / Liabilities measured at fair value through P\L(Accounted)	As at Sep 30, 2025		
	Level 1	Level 2	Level 3
Financial liabilities	-	-	-
Financial Assets	-	-	-

(₹ in Lakhs)

Assets / Liabilities measured at fair value through P\L(Accounted)	As at March 31, 2025		
	Level 1	Level 2	Level 3
Financial liabilities	-	-	-
Financial Assets	-	-	-

10. Earnings per share (EPS)

Particulars	Half year ended Sep 30, 2025	Year ended 31 March 2025
Net profit\ (loss) for the year attributable to equity shareholders (₹ in Lakhs)	(0.07)	(0.17)
Weighted average number of equity shares outstanding	20000	20000
Basic and diluted earnings per share (face value of Rs. 5 each)	(0.35)	(0.85)

11. Related Party Disclosures as per Ind AS-24

Relationship

- India Glycols Limited (100% holding company)
- Shahshi Kant Shukla (Director)
- Bhupendar Pal Singhal (Director)
- Manish Chandra Pant (Director)



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to the financial statements for the half year ended September 30, 2025

Related party transaction

Nature of transactions	Related Party	(₹ in lakhs)	
		Half year ended Sep 30, 2025	Year ended 31 March 2025
Reimbursement of Expenses made	India Glycols Limited	0.12	Nil
Outstanding Payable at the end of the year	India Glycols Limited	0.13	0.01


12. Financial Ratio Analysis

S. NO.	Particulars	Half year ended Sep 30, 2025	Year ended 31 March 2025
1	Current Ratio* (Current assets/current liabilities)	-	-
2	Debt-to-Equity Ratio (D/E) (in times) (Total Debt/Total Shareholder's equity)	NA	NA
3	Debt service coverage ratio (in times) (Profit after tax+depreciation+interest on term loan)/(Debt repayment including interest)	NA	NA
4	Return on equity ratio* (Net Profit after tax/Total Shareholder's Equity)	0.16	0.47
5	Inventory Turnover ratio (in times) (Cost of Goods Sold/Average Inventory)	NA	NA
6	Trade receivable turnover ratio (Net Credit Sales/Average Trade Receivables)	NA	NA
7	Trade payable turnover ratio (Net Credit purchases/(Average Trade payables))	NA	NA
8	Net Capital Turnover ratio (Net Sales/(Average Working capital))	NA	NA
9	Net Profit Ratio (Net profit after tax/Net Sales)	NA	NA
10	Return on Capital employed* (Profit before interest and tax)/Capital employed	0.16	0.47
11	Return on investment (Net return on investment/cost of investment)*100	NA	NA

* Sep 30th 2025 being the six months end performance not comparable to full year 2025.

13. Other Statutory information

- a) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.



Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
Notes to the financial statements for the half year ended September 30, 2025

- b) There are no transactions and / or balance outstanding with companies struck off under section 248 of the Companies Act, 2013.
- c) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- d) The Company has not traded or invested in Crypto currency or Virtual Currency during the period.
- e) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - ii) provided any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- f) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:
- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - ii) provided any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- g) The Company does not any transactions which are not recorded in the books of accounts that have been surrendered or disclosed as income during the reporting period in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)
- h) The company does not have any investments through more than two layers of investment companies as per section 2(87) (d) and section 186 of Companies Act, 2013.


In terms of our report of even date attached

For and on behalf of the Board of
Ennature Bio Pharma Limited

For KN GUTGUTIA & CO.
Chartered Accountants
ICAI'S FRN 304153E


B.R. Goyal
Partner
M.No: 012172




Manish Chandra Pant
(Director)
DIN-08850173


Shashi Kant Shukla
(Director)
DIN-07117368

Place: Noida (UP)
Date: 21/01/2026